{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-23-000051","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.074384+00:00","generated_at":"2026-06-11T22:49:17.487528+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pliant Therapeutics reports Q2 loss of $41.2M; initiates Phase 2b IPF trial, expects PSC data Q3 2023","bullets":["Net loss $41.2M vs $29.5M prior year; R&D $33.0M, G&A $14.6M.","Cash, equivalents & short-term investments $555.2M; sufficient into H2 2026.","Initiated Phase 2b BEACON-IPF trial of bexotegrast in IPF (~270 patients, 160/320 mg).","INTEGRIS-PSC Phase 2a 12-week interim data from 40/80/160 mg cohorts expected Q3 2023.","Promoted Dr. Scott Turner to Chief Scientific Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-23-000051","json":"https://secwatch.observer/filing/0001746473-23-000051.json","markdown":"https://secwatch.observer/filing/0001746473-23-000051.md","text":"https://secwatch.observer/filing/0001746473-23-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000051/0001746473-23-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000051/plrx-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:49:17.487528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}